Adjunctive music improves the tolerability of intravenous ketamine for bipolar depression.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
27
4
2021
medline:
24
12
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Intravenous ketamine is an effective treatment of bipolar depression. One of its most important side-effects is a transient altered state of consciousness commonly referred to as dissociation. These states can be anxiety-provoking, distressing and even treatment-limiting, warranting research into mitigation strategies. In this article, we present two cases that demonstrate the potential of adjunctive music to diminish the distress associated with ketamine-induced dissociation - though not necessarily its degree - in bipolar 1 disorder. Both patients suffering from severe depression underwent their first ketamine infusion without music and opted for music with subsequent infusions. They reported that music significantly improved the tolerance of their dissociative symptoms, thereby reducing distress and facilitating subsequent treatments. Both patients achieved remission from their highly treatment-resistant depressive episodes following six ketamine infusions. This is the first report of music's benefits on ketamine for bipolar 1 depression, though there is precedence in the scientific literature on 'psychedelics' where the use of music in combination with medication-induced altered states has been studied. The principles regarding music selection that have resulted from this paradigm may be applicable to the use of ketamine in unipolar and bipolar depression. The optimal use of music with ketamine warrants further research.
Identifiants
pubmed: 33902087
doi: 10.1097/YIC.0000000000000363
pii: 00004850-202107000-00008
doi:
Substances chimiques
Ketamine
690G0D6V8H
Banques de données
ClinicalTrials.gov
['NCT03866174']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218-220Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association.
Andrashko V, Novak T, Horacek J, Klirova M, Brunovsky M (2019). Concurrent benzodiazepines undermine the antidepressant effect of ketamine. Eur Neuropsychopharmacol 29:S389–S390.
Beck AT, Kovacs M, Weissman A (1979). Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 47:343–352.
Beck AT, Steer RA, Ball R, Ranieri W (1996). Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67:588–597.
Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. (2020). Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord 264:527–534.
Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, et al. (2019). Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs 51:189–198.
Duman RS (2018). The Dazzling Promise of Ketamine. Cerebrum 2018:cer–c04.
Johnson M, Richards W, Griffiths R (2008). Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–620.
Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, et al. (2018). The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl) 235:505–519.
Pereira S, Brennan E, Patel A, Moran M, Wallier J, Liebowitz MR (2021). Managing dissociative symptoms following the use of esketamine nasal spray: a case report. Int Clin Psychopharmacol 36:54–57.
Schwertner A, Zortea M, Torres FV, Caumo W (2018). Effects of subanesthetic ketamine administration on visual and auditory event-related potentials (ERP) in humans: a systematic review. Front Behav Neurosci 12:70.
Short B, Fong J, Galvez V, Shelker W, Loo CK (2018). Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 5:65–78.
Studerus E, Gamma A, Vollenweider FX (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412.
Wilkowska A, Szałach Ł, Cubała WJ (2020). Ketamine in bipolar disorder: a review. Neuropsychiatr Dis Treat 16:2707–2717.